TY - JOUR
T1 - Primary Effusion Lymphoma cell death induced by Bortezomib and AG 490 activates dendritic cells through CD91
AU - Cirone, Mara
AU - Di Renzo, Livia
AU - Lotti, Lavinia Vittoria
AU - Conte, Valeria
AU - Trivedi, Pankaj
AU - Santarelli, Roberta
AU - Gonnella, Roberta
AU - Frati, Luigi
AU - Faggioni, Alberto
PY - 2012/3/7
Y1 - 2012/3/7
N2 - To understand how cytotoxic agent-induced cancer cell death affects the immune system is of fundamental importance to stimulate immune response to counteract the high mortality due to cancer. Here we compared the immunogenicity of Primary Effusion Lymphoma (PEL) cell death induced by anticancer drug Bortezomib (Velcade) and Tyrphostin AG 490, a Janus Activated Kinase 2/signal trasducer and activator of transcription-3 (JAK2/STAT3) inhibitor. We show that both treatments were able to induce PEL apoptosis with similar kinetics and promote dendritic cells (DC) maturation. The surface expression of molecules involved in immune activation, namely calreticulin (CRT), heat shock proteins (HSP) 90 and 70 increased in dying cells. This was correlated with DC activation. We found that PEL cell death induced by Bortezomib was more effective in inducing uptake by DC compared to AG 490 or combination of both drugs. However the DC activation induced by all treatments was completely inhibited when these cells were pretreated with a neutralizing antiboby directed against the HSP90/70 and CRT common receptor, CD91. The activation of DC by Bortezomib and AG 490 treated PEL cells, as seen in the present study, might have important implications for a combined chemo and immunotherapy in such patients.
AB - To understand how cytotoxic agent-induced cancer cell death affects the immune system is of fundamental importance to stimulate immune response to counteract the high mortality due to cancer. Here we compared the immunogenicity of Primary Effusion Lymphoma (PEL) cell death induced by anticancer drug Bortezomib (Velcade) and Tyrphostin AG 490, a Janus Activated Kinase 2/signal trasducer and activator of transcription-3 (JAK2/STAT3) inhibitor. We show that both treatments were able to induce PEL apoptosis with similar kinetics and promote dendritic cells (DC) maturation. The surface expression of molecules involved in immune activation, namely calreticulin (CRT), heat shock proteins (HSP) 90 and 70 increased in dying cells. This was correlated with DC activation. We found that PEL cell death induced by Bortezomib was more effective in inducing uptake by DC compared to AG 490 or combination of both drugs. However the DC activation induced by all treatments was completely inhibited when these cells were pretreated with a neutralizing antiboby directed against the HSP90/70 and CRT common receptor, CD91. The activation of DC by Bortezomib and AG 490 treated PEL cells, as seen in the present study, might have important implications for a combined chemo and immunotherapy in such patients.
UR - http://www.scopus.com/inward/record.url?scp=84857879286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857879286&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0031732
DO - 10.1371/journal.pone.0031732
M3 - Article
C2 - 22412839
AN - SCOPUS:84857879286
VL - 7
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 3
M1 - e31732
ER -